WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011
/PRNewswire/ — Merck (NYSE:
MRK), known as MSD outside the United States and Canada, and
Intercell AG (VSE: ICLL) today announced that following a
pre-specified interim analysis from the Phase II/III clinical trial
evaluating V710, an investigational vaccine for the prevention of
Staphylococcus aureus (S. aureus) infection, the independent Data
Monitoring Committee (DMC) recommended suspension of enrollment.
Although the trial did not meet the pre-specified futility
criteria, the DMC nonetheless recommended suspension of enrollment
pending further analyses of the benefit/risk profile of the vaccine
candidate. Merck and Intercell plan to provide a further update
when analyses have been completed.
S. aureus is a leading cause of hospital-acquired
infections. In addition to bloodstream infections with a mortality
rate of up to 35 percent, infections of bone, heart and other inner
organs can often lead to serious health complications and death.
Today, approximately 50 percent of S. aureus strains
isolated in hospitals worldwide are resistant to multiple
antibiotics, rendering staphylococcal disease management
increasingly difficult and challenging.
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its
business, including words such as “could,” “should,” “may,”
“expects,” “anticipates,” “believes,” “intends,” “estimates,” or
similar words. Such statements involve certain known and unknown
risks, uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of
Intercell AG to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Intercell AG is providing this